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Summ a r y
Mutations in VHL, which encodes von Hippel–Lindau tumor suppressor (VHL), are 
associated with divergent diseases. We describe a patient with marked erythrocy-
tosis and prominent mitochondrial alterations associated with a severe germline 
VHL deficiency due to homozygosity for a novel synonymous mutation (c.222C→A, 
p.V74V). The condition is characterized by early systemic onset and differs from 
Chuvash polycythemia (c.598C→T) in that it is associated with a strongly reduced 
growth rate, persistent hypoglycemia, and limited exercise capacity. We report 
changes in gene expression that reprogram carbohydrate and lipid metabolism, 
impair muscle mitochondrial respiratory function, and uncouple oxygen consump-
tion from ATP production. Moreover, we identified unusual intermitochondrial 
connecting ducts. Our findings add unexpected information on the importance of 
the VHL–hypoxia-inducible factor (HIF) axis to human phenotypes. (Funded by 
Associazione Italiana Ricerca sul Cancro and others.)
Oxygen-sensing pathways orchestrate phenotypic adjustments from the cellular to the whole-body level, allowing function and survival under a variety of conditions.1 The hypoxic response is exquisitely sensitive 
and dynamic, with relatively small changes in oxygen availability initiating tran-
scriptional and post-transcriptional responses.2 A fundamental process in this 
pathway is the ubiquitination and subsequent degradation of the hypoxia-inducible 
factors (HIFs), processes that are mainly regulated by the oxygen- and iron-depen-
dent activity of the prolyl hydroxylase domain (PHD) enzymes and that require von 
Hippel–Lindau tumor suppressor (VHL).3
VHL encodes four different isoforms (pVHL-213, pVHL-160, pVHL-172, and 
pVHL-X1).4 Mutations leading to VHL loss of function result in a number of dis-
eases with divergent features.5 These diseases include the VHL syndrome, an inher-
ited disorder due to germline VHL alterations that lead to a predisposition to the 
development, on a somatic second hit, of a variety of tumors and fluid-filled sacs 
(cysts) in several body regions6; sporadic tumors, such as cerebellar hemangioblas-
tomas, pheochromocytomas, and clear-cell renal-cell carcinoma7,8; and familial 
erythrocytosis type 2, caused by a biallelic germline VHL mutation (canonically 
c.598C→T [R200W], causing Chuvash polycythemia) that results in increased ex-
pression of HIF target genes.9 Different sporadic VHL mutations have been reported10 
in addition to the canonical R200W mutation; some of these mutations are as-
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sociated with severe clinical phenotypes. For 
example, D126N caused fatal pulmonary hyper-
tension in a homozygous patient.11
We present the clinical and molecular charac-
terization of a case of familial erythrocytosis 
type 2 associated with a congenital, marked 
decrease in VHL levels. The patient had very 
early systemic onset of the disorder, with prena-
tal bradycardia and severe neonatal hypoglyce-
mia. He underwent phlebotomy in his first days 
of life, and a polymorphic clinical phenotype 
developed. At the age of 12 years, he underwent 
clinical and genetic characterization that revealed 
homozygosity for a synonymous mutation in VHL 
(c.222C→A; p.V74V). The patient’s genetic back-
ground and disease-related features stray from 
canonical familial erythrocytosis type 212 and 
suggest a new syndrome characterized by reduc-
tion in growth rate and pleiotropic alterations 
in energy metabolism, underpinned by marked 
mitochondrial dysfunction and structural changes.
C a se R eport
The index patient, a son of healthy consanguine-
ous white Italian parents (Fig. S1A in Supple-
mentary Appendix 1, available with the full text 
of this article at NEJM.org; note that all supple-
mentary figures and tables are located in Sup-
plementary Appendix 1) was born by emergency 
cesarean section on evidence of prenatal brady-
cardia episodes. At birth, the index patient had 
severe hypoglycemia, which was treated with 
hydrocortisone for 1 month, and persistent brady-
cardia (Table 1). No signs of sepsis were detected. 
He received phototherapy for early neonatal jaun-
dice and underwent phlebotomy when he was a 
few days old for hemoglobin and hematocrit val-
ues higher than the 99th percentile for his age.
A few months after birth, he began to show 
a marked failure to thrive and was administered 
recombinant growth hormone for 4 to 6 weeks, 
with no signs of growth hormone deficiency it-
self. Owing to the persistent hypoglycemia, he 
was treated with diazoxide for 3 years, which 
normalized his fasting glucose levels. When he 
was 12 years old, the patient was admitted to the 
University of Campania Hospital, Naples, Italy, 
with several phenotypic and metabolic abnormali-
ties (Table 1), together with an abnormal cardiac 
rhythm, which manifested as bigeminal and 
trigeminal pulses and supraventricular prema-
ture beats (not judged as requiring treatment). 
At the age of 13 years, his height and growth 
velocity were 3.0 SD below the normal population 
mean for his sex and age; growth hormone– 
releasing hormone (GHRH) and arginine-stimu-
lation testing produced a growth hormone (GH) 
peak of 33.6 ng per milliliter (a normal response 
is in the mid-60s in this age group), highlight-
ing impairment in the GHRH–growth hormone–
insulin-like growth factor 1 (IGF1) pathway. He 
underwent therapy with recombinant human 
IGF1, starting at a dose of 0.04 mg per kilogram 
of body weight and increasing to a full dose of 
0.12 mg per kilogram. His growth velocity in-
creased by 50% in 4 months, and he reached a 
height of 159 cm, with his genetic target being 
162 to 178 cm (Fig. S1B). The patient is cur-
rently 22 years old.
He has undergone periodic phlebotomies of 
5 to 7 ml per kilogram since he was a few days 
old (lately every 3 to 4 weeks). Although described 
as detrimental in patients with Chuvash polycy-
themia,13 phlebotomy is currently the main pro-
phylactic treatment14 for symptoms such as severe 
headache and muscle cramps, possibly because 
of blood hyperviscosity. The pleiotropic effects 
of iron deficiency15 demand strict control of iron 
bioavailability: iron supplementation (80 mg of 
ferrous sulfate per day), implemented since the 
patient was 14 years old, produced normal cellu-
lar iron availability (total iron-binding capacity, 
402 μg per deciliter [72 μmol per liter]). The 
patient’s parents were similar to controls with 
respect to clinical and laboratory measures (not 
shown).
Me thods
Oversight
This study was approved by the institutional re-
view board of the University of Campania Luigi 
Vanvitelli. The patient and his parents provided 
written informed consent.
Genetic Analyses
The genetic and protein analyses were per-
formed on peripheral-blood mononuclear cells 
(PBMCs). VHL exons were amplified by poly-
merase chain reaction (PCR) and sequenced. 
VHL messenger RNA (mRNA) was quantified by 
reverse-transcriptase–quantitative PCR (RT-qPCR). 
Expression of hypoxia-dependent genes was in-
vestigated with a comprehensive array RT2 Pro-
filer PCR Array Human Hypoxia Signaling Path-
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way (Qiagen). Transcription levels of selected 
genes were confirmed by RT-qPCR. Immuno-
blotting was used to analyze protein levels. 
Whole-genome sequencing and bioinformatics 
analyses were performed by Admera Health.
Functional and Laboratory Studies
Respirometry analyses were performed on mus-
cle fibers. The in vivo phenotype of the index 
patient was characterized by investigating exer-
cise capacity and cardiopulmonary responses to 
acute hypoxia (end-tidal partial pressure of oxy-
gen, 50 mm Hg).
Blood and red-cell membrane lipids were 
studied by means of high-performance liquid 
chromatography and gas chromatography. Mus-
cle metabolites were analyzed by ultra-high-
performance liquid chromatography–mass spec-
trometry. Muscle ultrastructure was studied with 
transmission electron microscopy. Additional 
methodologic details, including details of the 
methods used to evaluate glycemia, are provided 
in Supplementary Appendix 1.
R esult s
Mutational Analysis and Transcriptional  
and Biochemical Characterization
Direct sequencing of the exons and exon–intron 
boundaries of the VHL gene revealed homozy-
gosity for a novel mutation causing a synony-
mous variation, p.V74V (c.222C→A) (Fig. 1A). To 
support the identification of pathogenic VHL 
mutations and to investigate the occurrence of 
other possible pathologic genetic variants, whole-
genome sequencing of the patient and his par-
ents was performed (Supplementary Appendix 1). 
Three groups of mutations were highlighted: 
mutations for which the patient was homozy-
gous and his parents were simple heterozygous 
(Supplementary Appendix 2), mutations for which 
the patient was homozygous and the parents 
were compound double heterozygous (Supple-
mentary Appendix 3), and mutations for which 
the patient was double heterozygous, with one 
mutation inherited from the heterozygous 
mother and one inherited from the heterozy-
gous father (Supplementary Appendix 4).
A total of 249,010 mutations were identified, 
with only 1134 (0.46%) being exonic (Fig. S1C). 
As discussed in Supplementary Appendix 1, the 
use of predictive software for identifying dam-
aging mutations or for pathway analysis identi-
Measure Value in Patient Reference Range
At birth
Hematocrit (%) 73 42–64
Hemoglobin (g/dl) 22.5 14–19.9
Glucose (mg/dl) 24 45–100
17-Hydroxyprogesterone (μg/liter) 55 0.7–43
Insulin (μU/ml) 1.28 2.42–13
Heart rate (beats/min) 85 120–160
At genetic diagnosis (12 yr of age)
Hematocrit (%) 62 35–46
Hemoglobin (g/dl) 19.8 12.2–15.4
Erythropoietin (mU/ml) 496 1.6–34
Ferritin (ng/ml) 6 20–150
GHRH+arginine test, GH peak (ng/ml) 33.6 5–12
Height (cm) 132.3†
Glucose (mg/dl) 42 60–100
Blood pressure (mm Hg) 75/35‡
Venous lactate (mmol/liter) 2.3 <1
Arterial blood gas analysis
pH 7.41 7.38–7.42
pCO2 (mm Hg) 24.8 35–45
pO2 (mm Hg) 121 83–105
cHCO3− (mmol/liter) 15.6 22–26
cBASE (mmol/liter) −8.1 −2 to 2
At 22 yr of age
Hematocrit (%) 55.5 37–49
Hemoglobin (g/dl) 17.5 12.5–16.5
Reticulocyte count (cells/μl) 175,000
Ferritin (ng/ml) 18 20–150
Total iron-binding capacity (μg/dl) 402 240–450
Insulin (μU/ml) 3.5 3–8
Glucose (mg/dl) 49 60–100
Cholesterol (mg/dl) 95 60–200
HDL cholesterol (mg/dl) 31 >35
LDL cholesterol (mg/dl) 55 <129
Total cholesterol:HDL cholesterol ratio 3.13  
*  The main anomalous clinical and laboratory measures at each indicated age 
are shown. Reference values are the normal values for age and sex. The pa-
tient has been treated with monthly phlebotomies, iron supplementation, and 
periodic antihistaminic treatments. To convert the values for cholesterol to 
millimoles per liter, multiply by 0.02586. To convert the values for glucose to 
millimoles per liter, multiply by 0.05551. To convert the values for iron-bind-
ing capacity to micromoles per liter, multiply by 0.1791. To convert the values 
for insulin to picomoles per liter, multiply by 6.945. The term cBASE denotes 
base excess in blood, cHCO3− concentration of bicarbonate, GH growth hor-
mone, GHRH growth hormone–releasing hormone, HDL high-density lipo-
protein, LDL low-density lipoprotein, pCO2 partial pressure of carbon dioxide, 
and pO2 partial pressure of oxygen.
†  The patient’s height was 3 SD below the population mean for his age and sex.
‡  The patient’s systolic blood pressure was 2 SD below the mean for his age and 
sex; his diastolic blood pressure was in the 3rd percentile for his age and sex.
Table 1. Clinical and Laboratory Measures.*
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fied no variation that was clearly related to the 
patient’s phenotype (Supplementary Appendixes 
5 and 6). The c.222C→A change created a cryp-
tic donor splicing site at nucleotide position 220 
(NetGene2 and FSPLICE). RNA was analyzed to 
characterize the effect of the c.222C→A change 
on splicing. Primers annealing on exons 1 and 2 
of the VHL complementary DNA (cDNA) were 
designed to produce a 493-bp amplicon. A VHL
RT-PCR analysis revealed an additional band of 
372 bp in the patient (II1 in Fig. 1B). The pa-
tient’s father (I1) had a smaller amount of the 
anomalous transcript, and a control had only the 
longer transcript. Sequence analysis showed that 
the aberrant transcript was missing 121 bp, 
from nucleotide 220 to 340 (Fig. 1B). The aber-
rant splicing led to a shorter exon 1, causing a 
frameshift with an anomalous stop codon, 
which would in theory produce a shorter protein 
(Fig. 1C).
The full-length VHL mRNA levels in the pa-
tient and his father were approximately 80% and 
40% lower, respectively, than those in a control 
participant (Fig. 1D). Levels of the three main 
VHL protein isoforms (pVHL-213, pVHL-160, and 
pVHL-172) were clearly reduced (Fig. 1E), suggest-
ing impairment in VHL-dependent functions. 
Correspondingly, the HIF-1α nuclear immuno-
fluorescence signal in the patient’s lymphocytes 
was strongly enhanced as compared with that in 
a healthy control (Fig. S1D). According to the 
American College of Medical Genetics and Ge-
Figure 1. Effects of the Mutation on VHL Levels.
Panel A shows a sequence chromatogram for VHL, which encodes von Hippel–Lindau tumor suppressor (VHL); the normal and mutated 
genome are shown, highlighting (in the box) the homozygous mutation at nucleotide 222 (C→A). The identified mutation affects VHL
transcript maturation, since it creates an alternative donor site and causes a 121-bp loss of VHL mature RNA transcript. Panel B shows 
electrophoretic analysis of reverse-transcriptase–polymerase-chain-reaction (RT-PCR) products with primers designed against exons 
1 and 2 (lane 1, molecular weight marker; lane 2, control participant [CTR]; lane 3, index patient [II1]; lane 4, index patient’s father [I1]). 
The sequence chromatogram shows the anomalous short band (372 bp) with 121-bp loss. Panel C shows normal and mutated VHL
messenger RNA (mRNA) splicing, illustrating the reduction of exon 1. Altered splicing caused a shift in the open reading frame and 
originates a premature stop codon. Panel D shows quantification of VHL mRNA in a control, the father of the index patient, and the 
 index patient, from an analysis of a specific exon 2 region. Quantitative RT-PCR (RT-qPCR) was performed on total peripheral-blood 
mononuclear cell (PBMC) mRNA. Mean values from three independent evaluations are shown and are expressed as the ratio of the 
mRNA level in the patient to that in the control; I bars indicate the standard deviation. P values are for the comparison with control. 
 Panel E shows Western blot analysis of VHL protein isoforms in PBMCs from a control and from the patient. VHL antibodies were directed 
against an epitope occurring in normal and mutated VHL. Tubulin (TUB) is a control for loading. The filter stained with ponceau red is 
shown to confirm equal loading.
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nomic Guidelines, the c.222C→A VHL mutation 
can be classified as likely to be pathogenic, 
satisfying one strong and two moderate crite-
ria.16 The genetic change has been deposited in 
ClinVar repository under the accession number 
SCV000924583.
Exercise Capacity and Cardiopulmonary 
Responses to Acute Hypoxia
The patient had serious hypotension at diagnosis 
(blood pressure, 75/35 mm Hg), a condition not 
described in other forms of familial erythrocyto-
sis, including classical familial erythrocytosis 
type 2, type 3 (due to PHD2 loss of function), and 
type 4 (due to HIF2A gain of function).17 To 
evaluate the phenotype associated with the ge-
netic mutation, the patient’s exercise capacity 
and response to hypoxic cardiopulmonary stress 
were tested with standard procedures.18 The pa-
tient had elevated arterial partial pressure of 
oxygen, reduced arterial partial pressure of car-
bon dioxide, and reduced arterial bicarbonate 
(Table 1). At baseline while he was breathing 
ambient air, the patient’s end-tidal partial pres-
sure of oxygen was high, the end-tidal partial 
pressure of carbon dioxide was low, and the re-
spiratory quotient was 0.803; this altered venti-
latory control has been observed in Chuvash 
polycythemia19 and mimics acclimatization to 
high-altitude hypoxia, overall suggesting the 
central role of the VHL–HIF pathway in the cali-
bration of cardiopulmonary system physiology. 
The precise mechanisms underpinning altered 
ventilation remain to be elucidated. However, a 
study involving a mouse model of Chuvash poly-
cythemia showed the occurrence of carotid-body 
hyperplasia and enhanced sensitivity to hypoxia.20
End-tidal partial pressure of oxygen and car-
bon dioxide were accurately controlled through-
out the acute hypoxia exposure protocol; in 
particular, end-tidal partial pressure of carbon 
dioxide was controlled to reflect values observed 
at rest and from the arterial blood gas analysis 
(Fig. 2A). The patient’s pulmonary arterial sys-
tolic pressure and cardiac output were elevated 
at baseline and increased markedly in response 
to hypoxia, similar to findings in patients with 
Chuvash polycythemia.21
The patient had a limited exercise capacity, 
associated with a low peak level of lactate in 
venous blood (Fig. 2B). Moreover, he had a 
greater than normal increase in ventilation for 
equivalent work rates, while end-tidal partial pres-
sure of carbon dioxide remained low throughout 
the exercise protocol (Fig. 2B). These integrative 
aspects of the phenotype associated with the 
mutation in this patient partly recapitulate those 
described in Chuvash polycythemia.21
Changes in Gene Expression  
and Mitochondrial Alterations
In contrast to findings in patients with Chuvash 
polycythemia,22 markedly altered expression of 
several HIF target genes was found in the analy-
sis of RNA from the patient’s PBMCs (Fig. 2C 
and Supplementary Appendix 1). IGFBP3 (encod-
ing insulin-like growth factor–binding protein 3) 
RNA levels were 80% lower than in either pa-
tients with Chuvash polycythemia or healthy 
controls (Fig. S1E). Lower IGFBP3 expression has 
been reported in conditions under which activity 
of the GH–IGF1 axis is reduced.23
BNIP3L and MXI1 are two key mitochondria-
modulating genes. BNIP3L is a receptor account-
able for stress-induced mitophagy,24 and MXI1 is a 
negative transcriptional regulator of MYC, which 
is involved in mitochondrial biogenesis and me-
tabolism.25 RT-qPCR analysis showed that expres-
sion of BNIP3L and MXI1 was more than 25 and 
45 times as high, respectively, in our patient as 
in two controls, whereas there was no signifi-
cant difference between the controls and two 
patients with Chuvash polycythemia with Italian 
heritage who were matched to our index patient 
for hematologic and iron measures (Fig. 2D). 
BNIP3L, MXI1, and IGFBP3 expression in the pa-
tient’s parents did not differ from that in con-
trols (not shown). BNIP3L and MXI1 expression 
was previously found to be enriched to a minor 
degree in a cohort of Russian patients with Chu-
vash polycythemia (1.31 and 1.18 times as high 
as normal, respectively), with low ferritin levels 
positively correlating with expression.22 BNIP3L 
and MXI1 up-regulation in our patient was con-
firmed at the protein level, suggesting marked 
mitochondrial dysfunction (Fig. 2E). Given the 
degree of these alterations that were found in 
the patient but were absent in patients with 
canonical familial erythrocytosis type 2, we in-
vestigated skeletal muscle mitochondrial func-
tion and morphology in vastus lateralis biopsy 
specimens.
Mitochondrial respiratory function was as-
sessed in saponin-permeabilized muscle fibers 
with the use of high-resolution respirometry.26 
This revealed a marked suppression in the pa-
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tient’s muscle mitochondrial respiratory capacity 
relative to that in a control (Fig. 3A). The oxida-
tive phosphorylation capacity supported by fatty-
acid substrates (OctMP) was 28% lower in the 
patient, and oxidative phosphorylation capacities 
supported by substrates for electron transport 
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chain complex I (GMP) and for complexes I and 
II in combination (GMSP) were 44% and 34% 
lower, respectively. LEAK respiration (i.e., oxygen 
consumption in the absence of ATP synthesis 
[OctML]) per unit muscle mass did not differ; 
however, it was 31% higher when expressed rela-
tive to electron transport chain capacity, with 
LEAK respiration making up a greater propor-
tion of total oxygen consumption. Together, these 
data indicate that the patient’s muscle mito-
chondrial respiratory capacity was substantially 
low, but with greater LEAK respiration per mito-
chondrial unit, which suggests that there was 
uncoupling of oxygen consumption from ATP 
production. The suppression of mitochondrial 
respiratory capacity and fatty-acid oxidation re-
sembles that seen in healthy humans acclimatiz-
ing to high-altitude hypoxia.26 Electron micros-
copy revealed that the patient had high levels of 
unusual intermitochondrial connecting ducts 
(similar to cardiac nanotunnels) extending from 
mitochondria in a direction perpendicular to the 
long axis of the fiber (Fig. 3B). These ducts have 
been observed only in mitochondrial myopathy27,28 
and, to a much lesser extent, in normal muscle.29 
They can form an extensive network for physio-
logical exchanges, possibly contributing to mito-
chondrial survival under stress conditions.
Glucose and Lipid Metabolism
We investigated the patient’s glucose and lipid 
metabolism in light of the metabolic shift from 
oxidative phosphorylation to glycolysis associated 
with VHL loss of function. GLUT-1, a uniporter 
supporting cellular glucose entry that is under 
transcriptional control by HIF-1α, was increased 
at the RNA and protein levels (Fig. S1F and S1G). 
Metabolomic analysis of muscle tissue high-
lighted that levels of almost all glycolytic inter-
mediates were substantially lower in the patient 
than in the control (by 81 to 98%) (Table 2). Low 
levels of glycolytic metabolites in association 
with increased GLUT-1 and high levels of circu-
lating lactate suggest that glucose utilization by 
muscle was enhanced, which accounts for the 
remarkable venous hypoglycemia (Table 1). Pa-
tients with familial erythrocytosis type 2 have 
been described as having a lower mean blood 
glucose level than controls, albeit still within the 
physiologic range, with the lower quartile of 
patients having glucose levels lower than 56 mg 
per deciliter (3.1 mmol per liter).30 The levels of 
all tricarboxylic acid cycle intermediates (from 
α-ketoglutarate to malate) were reduced in the 
index patient’s muscle, alongside slightly higher 
levels of citrate and isocitrate than in the control 
and an oxaloacetate level that was 10 times as 
high as in the control (Fig. S2A). The difference 
in oxaloacetate levels could result from altered 
aspartate metabolism and might explain the ele-
vated citrate levels. High cellular citrate and oxalo-
acetate levels might also originate from increased 
Figure 2 (facing page). Exercise Capacity and Gene 
 Expression.
Panel A shows the mean (±SD) end-tidal partial pressure 
of oxygen and carbon dioxide, cardiac output, heart 
rate, ventilation, and saturation at baseline and in re-
sponse to acute exposure to hypoxia in the patient and 
in healthy controls. Pulmonary arterial systolic pressure 
(PASP) values are shown for 15 healthy control partici-
pants. Panel B shows lactate concentration, ventilation, 
and end-tidal partial pressure of carbon dioxide as a 
function of work rate on the cycle ergometer; the values 
for the patient (II1) are minute means and standard de-
viations (I bars) recorded over the course of two tests. 
The results for 6 healthy controls are shown for compari-
son; controls stopped exercising later in the protocol 
(mean maximal work rate, 240 watts; data not shown). 
Panel C shows gene-expression profiles of several 
 hypoxia-related genes, evaluated with a comprehensive 
RT-PCR array in patient PBMC total RNA and shown as 
a scatterplot of data for the patient and a control (from 
three independent experiments). ΔCt is the difference 
between the cycle threshold for the gene of interest 
and the mean cycle threshold from five reference genes. 
Red data points indicate genes with significantly higher 
expression in the patient than in the control, and pur-
ple data points indicate genes with significantly lower 
expression in the patient than in the control; expression 
of the genes indicated by blue data points did not dif-
fer significantly between the patient and the control. 
The genes with the largest deviation from the control 
were BNIP3L and MXI1. SLC2A1 (encoding GLUT1, a 
glucose transporter) is also highlighted, since this gene 
has been studied in relation to the metabolism of glu-
cose. Numbers shown next to these three genes are 
the estimated ratio of expression in the patient to ex-
pression in the control. BNIP3L and MXI1 transcripts 
(Panel D) were quantified in two controls (CTR1 and 
CTR2), the patient (II1), and two patients with Chuvash 
polycythemia (CP1 and CP2) by RT-qPCR performed 
on PBMC total mRNA. The mRNA levels were normal-
ized to a standard (β-actin). The results are the means 
and standard deviations (I bars) of three independent 
evaluations. The P value is for the comparison with 
control; NS denotes no significant difference. Panel E 
shows levels of both BNIP3L and MXI1 proteins, ana-
lyzed by Western blot in PBMC protein extracts from 
the control (CTR) and the patient (II1); levels of these 
proteins were higher in the patient than in the control. 
Histone deacetylase 1 (HDAC1) was used as a control 
for equal loading.
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glutamine metabolism, as has been observed in 
patients with VHL deficiency. Lower levels of all 
amino acids studied were seen, possibly because 
of their consumption as a carbon source for 
energy metabolism (Table 2). Muscle ATP levels 
and energy charge (a marker of the energy status 
of the tissue) were substantially lower (79%) in 
the patient, and the phosphocreatine level was 
24% lower. The ratio of oxidized to reduced glu-
tathione was 2.44 times as high in the patient, 
which suggested greater in vivo oxidative stress 
(Fig. S2B).
Lipid metabolism was evaluated in blood. The 
patient had low levels of high-density lipoprotein 
(HDL) cholesterol (Table 1), with a total:HDL 
cholesterol ratio that suggested a low risk of 
ischemic heart disease.31 Low cholesterol levels 
may be related to the HIF-dependent activation 
of INSIG2 (insulin induced gene 2) expression. 
INSIG2 is a key negative regulator of fatty acids 
and cholesterol biosynthesis32 and directly induces 
degradation of β-hydroxy-β-methylglutaryl-CoA 
reductase.33 This up-regulation was not observed 
in patients with Chuvash polycythemia (Fig. S2C) 
or any other human disease.
As compared with healthy persons,34 the 
patient’s fatty-acid distribution in whole blood 
showed lower levels of monounsaturated fatty 
Metabolite or Amino Acid Ratio (Patient:Control)
Metabolites
Glucose-6-phosphate 0.05
Fructose-6-phosphate 0.05
Fructose 1,6-bisphosphate 0.12
Glyceraldehyde-3-phosphate 0.16
Dihydroxyacetone phosphate 0.12
Bisphosphoglycerate 1.22
2- and 3-Phosphoglycerate 0.14
Phosphoenolpyruvate 0.19
Pyruvate 0.02
Amino acids
Ornithine 0.22
Asparagine 0.16
Aspartate 0.44
Glutamine 0.15
Glutamate 0.30
Proline 0.20
Valine 0.22
Isoleucine 0.26
Leucine 0.26
*  Metabolomic data were obtained by ultra-high-performance 
liquid chromatography–mass spectrometry of extracts 
 derived from biopsy specimens of the vastus lateralis. 
Data obtained for each glycolytic metabolite and amino 
acid were normalized to the total protein levels and are 
shown as ratios (patient:control).
 Table 2. Metabolomic Data.*
Figure 3. Effects of Low Levels of VHL on Mitochondrial Respiratory Activity.
Panel A shows a functional evaluation of vastus lateralis biopsy specimens; 
on the left, the mitochondrial respiration rates are corrected for the wet 
mass of muscle and include LEAK state respiration (i.e., oxygen consump-
tion in the absence of ATP synthesis) with malate and octanoyl carnitine 
(OctM
L
); oxidative phosphorylation (OXPHOS)–state respiration with ma-
late and octanoyl carnitine (OctM
P
); OXPHOS-state respiration through the 
N pathway by complex I with glutamate and malate (GM
P
); OXPHOS-state 
respiration through NS pathways by complex I and II with glutamate, succi-
nate, and malate (GMS
P
); and electron transport chain capacity by titration 
of the mitochondrial uncoupler FCCP (GMS
E
). On the right, the respiratory 
states are instead corrected for GMS
E
. Data are the means obtained from 
duplicate experiments on the same muscle-biopsy specimen in both a con-
trol and the patient. Differences are shown above the bars as percentages. 
Panel B shows a transmission electron microscopy analyses of vastus lateralis–
biopsy specimens from a control (CTR) and the patient (II1). The image on 
the right shows mitochondrial extensions (arrows). These extensions are 
larger than T tubules and are located at the same level as mitochondria 
bodies, on either side of the Z line and in close proximity to it. They provide 
direct continuity between mitochondria and are not associated with a triad.
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acids, especially palmitoleic acid (C16:1) and oleic 
acid (C18:1), and an arachidonic acid:eicosapen-
taenoic acid ratio that was 4 times as high (Fig. 
S2D), suggesting increased inflammation in the 
patient.35 No substantial difference in circulating 
malondialdehyde was observed between the pa-
tient and controls (Fig. S2E), implying that there 
was not a substantial degree of lipid peroxidation. 
Red-cell membranes in the patient had altered 
lipid compositions (Fig. S2F), which could lead 
to increased deformability and decreased aggre-
gation and thrombotic risk.
Discussion
The increase in HIF levels caused by VHL loss of 
function, due to either hereditary or acquired 
mutations, underpins a large spectrum of dis-
eases with different features. Classic VHL syn-
drome, which is generally caused by hereditary 
allele inactivation plus a tissue somatic muta-
tion, is characterized by the occurrence of can-
cers and increased expression of genes, includ-
ing VEGF, that allow tumor development and 
progression. In contrast, hereditary VHL mis-
sense mutations can result in erythrocytosis as-
sociated with a variety of generally mild symp-
toms, without development of cancers,17 as is seen 
with the R200W mutation, which is endemic in the 
Chuvash region (Russia) and in Ischia (Italy).36,37
Molecular and clinical studies highlighted dif-
ferences between the index patient and patients 
with canonical familial erythrocytosis type 2 
carrying the R200W homozygous mutation. 
Homozygosity for the c.222C→A mutation was 
associated with a severe, congenital decrease in 
functionally normal VHL, along with a novel 
pleiotropic syndrome characterized by a reduced 
growth rate, hypotension, persistent hypoglyce-
mia, erythrocytosis from birth, limited exercise 
capacity, and marked metabolic alterations, in-
cluding reduced oxidative phosphorylation ca-
pacity. Studies in animal models showed that 
HIF up-regulation impairs the GH–IGF1 axis, 
affecting growth rate and down-regulating 
IGFBP3 mRNA expression.38 In our patient, the 
robust HIF activation might have altered the 
GH–IGF1 axis, causing a reduction in the growth 
rate. GH–IGF1 impairment was confirmed by de-
creased IGFBP3 mRNA and by the positive effect 
of IGF1 treatment on growth rate.
Many additional clinical features are likely to 
be related to altered skeletal-muscle metabolism. 
Our patient has greatly reduced mitochondrial 
respiratory capacity, probably as a consequence 
of HIF-dependent gene expression. Although HIF-
related transcriptome analysis (confirmed at the 
protein level) revealed a high level of promi-
tophagy signals, muscle mitochondrial density 
(as opposed to respiratory capacity) was unaffect-
ed, in contrast to findings in adapted Tibetan 
highlanders.26
Electron microscopy revealed that muscle 
mitochondria had an unexpectedly high number 
of microtubular extensions, which were clearly 
connected to mitochondria at both ends and 
thus allowed equilibrium of membrane potential 
and exchange of solutes over long distances. 
These structures create a dynamic communica-
tion network, potentially contributing to mito-
chondrial survival under conditions of stress by 
counteracting autophagic stimuli.
Phlebotomy to reduce erythrocytosis causes 
iron deficiency, which can alter energy metabo-
lism.39 In our patient, long-term iron supple-
mentation was sufficient to partially restore 
concentrations of non–transferrin-bound iron and 
ferritin, which were higher than in patients with 
Chuvash polycythemia (median ferritin level, 14 ng 
per milliliter among 24 patients) with mildly 
altered gene expression.22 The mitochondrial 
abnormalities observed in our patient are dis-
tinct from those in patients with iron defi-
ciency,40 which only mildly reduces the lactate 
threshold in humans. The unique, complex clini-
cal phenotype observed in our patient might arise 
from the mitochondrial dysfunction, other deregu-
lated pathways, and, probably, as-yet-undescribed 
adaptive mechanisms.
We conclude that this newly identified syn-
drome is a direct demonstration of the exqui-
sitely sensitive interaction between VHL and HIF 
in the regulation of human metabolism and 
skeletal-muscle function.
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